Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.


NDAQ:ACST - Post by User

Post by LifeGoesOn1973on Jan 03, 2020 7:50am
179 Views
Post# 30514391

lots of misinformation going on here

lots of misinformation going on here
1) regarding the Vascepa numbers, it is 33% improvement over placebo and not 24% as Francine said. 2) we already reduced TG by 15% in the severe strata in the 2 g in the Trifecta trial (confirmed by Pierre Lemieux in his latest Interview), Vascepa reduction was 7% so we are already double the values of Vascepa, does this trend continue with the 4 g ? I doubt it will be double but I am very optimistic. 3) regarding the recent drama in the SP, I acknowledge that management should have been less careless with the delay announcement by issuing the PR earlier but this is inconsequential because what matters the most is the quality of the results 4) Regarding talk about leak of the delays, ok it happens all the time leaks get out to privy investors this is not new so get over it, next time don't put stop losses in an extremely volatile sector. 5) The fact that company is willing to wait for secondary results before issuing the TG results is bullish since it is meaningless to issue secondary when primary fail. 6) regarding prediction of stock price, no one knows so stop speculating, analysts gives it up to 10 USD but again it depends on results, if we can equal or beat Vascepa with TG and prove better secondary then the sky is the limit, and if the HBA1c results prove reduction then expect additional increase of SP. 7) Right now all we can do is wait, lots of traders are playing this stock and the raid on Dec 23 is the biggest example, just ignore the noise and everyone's opinion (seeking alpha or VAS Research,, or others), don't put stop losses, go back to the fundamentals of the company, unless they change then just ignore the noise and wait for results
<< Previous
Bullboard Posts
Next >>